Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

BMO Mid-Cap Growth Fund Class I (MRMIX)

20.30
Net Asset Value
+1.81%
1 Day
-3.43%
Year-to-Date
Overall Morningstar Rating
Mid-cap growth
Style or Category
No Load
Sales Expenses
0.97%
Expense Ratio
Above Average
Morningstar Risk Rating™
Investment Objective The investment seeks capital appreciation. The fund invests at least 80% of its assets in growth-oriented common stocks of medium-sized U.S. companies similar in size, at the time of purchase, to those within the Russell Midcap  Growth Index. The Adviser selects stocks of companies with growth characteristics, including companies with above average earnings growth potential and companies where significant changes are taking place, such as new products, services, methods of distribution, or overall business restructuring.

Performance

1 month-10.14% 3 years+11.25%
3 months-10.22% 5 years+13.35%
1 year-5.31% Since inception+8.90%
Data through --

Peer Comparisonvs. Mid-cap growth

 MRMIXCategory
Performance 5-yr return+13.35%+16.81%
Expense ratio0.97%1.31%
Risk 5 year sharpe ratio1.001.07
Net assets$225.8M$1.4B
Average market cap$7.5B$9.8B
Average P/E30.825.2
Portfolio turnover----

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyBMO Funds
Fund manager & tenureKenneth Salmon / 10 Years
Minimal initial investment$2,000,000.00
Minimum IRA investment--

Holdings

U.S. stock86.27%
International stock10.24%
Cash1.80%
Fixed income1.69%
Other0.00%
Top 5 Sectors
Portfolio weighting
Industrial materials 21.03%
Healthcare 14.41%
Energy 10.97%
Consumer service 9.39%
Consumer goods 8.22%
Top 10 Holdings
Portfolio weighting
CRTO Criteo SA2.29%
SSTK Shutterstock Inc1.94%
CATM Cardtronics Inc1.74%
GLNG Golar LNG Ltd1.67%
DLTR Dollar Tree Inc1.59%
TPH TRI Pointe Group Inc1.53%
GLOG GasLog Ltd1.49%
CERN Cerner Corp1.41%
EVHC Envision Healthcare Holdings Inc1.40%
JAZZ Jazz Pharmaceuticals PLC1.38%

Partner Offers